Clinical Trial Search

Primary: Change From Baseline in Total Body Fat Composition Using Dual Energy X-ray Absorptiometry at 12 Weeks — -0.51; 2.03 percent change — p=< 0.0001

Primary: Percent Change From Baseline in Body Weight at Week 24 — 6.59; 4.21 Percent change in body weight — p=0.003

Primary: Sinonasal Outcome Test - 22 — 31.3; 31.0 score on a scale

Primary: Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24 — 85; 40 Participants — p=<0.001

Primary: Percentage Of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26 — 53.6; 83.9; 76.8; 58.9 percentage of participants

Primary: Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3 — -10.6; -10.8 units on a scale — p==0.8797

Primary: Number of Participants With >20 on the 26 Children Eating Attitudes Test — 26; 4 Participants

Primary: Complete Reversal — 80 percentage of participants

Primary: Th1/Th2 Normalized Gene Expression — 1.029; 0.119; 0.074; 0.192 fold change

Primary: Skin Conductance Response — NA; NA skin conductance responses per second

Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer

Primary: Number of Participants With Early Onset Primary Adverse Events (PAEs): Death, Atrio-esophageal Fistula and Pulmonary Vein Stenosis — 0 Participants

Primary: Mean Change in Unified Parkinson's Disease Rating Scale (UPDRS) Scores - Motor Section (Part III) at End of Randomized Phase — 21; 21; 13; 16 units on a scale

Primary: Number of Subjects With 12 Month Clinical Outcomes (MACE) Major Adverse Cardiac Events by FFR Values and Resting Indices — 50; 51; 19; 30 Participants

Primary: Number of Participants Who Were Intubated — 6; 8 Participants